Spinal and Bulbar Muscular Atrophy Spinal and Bulbar Muscular Atrophy
Conditions
Interventions
Mexiletine hydrochloride 300 mg or placebo is administered orally divided into three times a day after meals for 12 weeks.
Sponsors
Katsuno Masahisa
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Male patients with a CAG repeat count of 38 or more for the androgen receptor gene in genetic testing and a confirmed diagnosis of SBMA 2) Patients with muscle weakness (limb weakness and atrophy, or bulbar palsy) due to lower motor neuron lesion 3) Patients with a total ALSFRS-R score of >= 24 and <= 42 at screening 4) Patients who are at least 18 years old and less than 80 years old at the time of consent 5) Patients who give their voluntary written consent after having received adequate information on this study (However, if the patient is unable to sign the consent form due to the condition of the disease, a person equivalent to a regal representative must be present to provide written explanation, the prospective candidate must verbally consent to participate in the study, and a person equivalent to a regal representative must sign the consent form on behalf of the patient. The person who is to be the regal representative may sign the document on his/her behalf, noting the circumstances and his/her relationship to the subject.)
Exclusion criteria
Exclusion criteria: 1) Patients who have participated or are participating in a clinical trial within 12 weeks prior to enrollment 2) Patients with a history of hypersensitivity to any component of this drug product 3) Patients with a conduction disturbance (such as second- or third-degree atrioventricular block without a pacemaker, or left bundle branch block) 4) Patients with Brugada-type ECG 5) Patients with severe heart failure or heart disease (myocardial infarction, valvular disease, cardiomyopathy, etc.) 6) Patients with sinus bradycardia (<50 beats/minute) 7) Patients with systolic blood pressure of 90 mmHg or less 8) Patients with serum potassium level less than 3.5 mmol/L 9) Patients on antiarrhythmic drugs 10) Patients on antiepileptic drugs that affect to sodium channels 11) Patients on theophylline 12) Patients on narcotics 13) Patients who used Mexiletine within 1 month prior to enrollment or used Mexiletine for expectations of improvement in symptoms of SBMA 14) Patients with serious complications 15) Patients who cannot agree to use contraception during the study period 16) Other Patients deemed inappropriate by the investigator or subinvestigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALSFRS-R Score | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) SBMAFRS score 2) Grip strength 3) Tongue pressure 4) Timed walk test (4.6 meters) 5) 6-minute walk test 6) Respiratory function test (FVC, PEF) | — |
Contacts
Public ContactShinobu Shimizu
Nagoya University Hospital
Outcome results
None listed